Chikungunya virus (CHIKV) recently emerged from Africa into an urban human-mosquito cycle to cause millions of cases of highly debilitating, often chronic arthralgic disease. Dozens of CHIKV importations via viremic travelers underscore the risk of CHIKV to the Western hemisphere. There is no effective treatment for chikungunya fever (CHIK), which can be fatal, so an effective vaccine is needed. For use in third world, endemic locations, an ideal vaccine must be inexpensive to manufacture and induce rapid, long-lived immunity after a single dose. To be used safely in nonendemic locations, the vaccine must also be incapable of infecting mosquito vectors in the event that viremia occurs in a vaccinee with impaired host defense. To achieve these goals, we developed novel, innovative approaches to stable alphavirus attenuation that retain immunogenicity yet eliminate the possibility of mosquito infection. Using a picornavirus internal ribosome entry site (IRES) that functions poorly in insect cells, combined with inactivation of the alphavirus subgenomic promoter that drives overexpression of the structural proteins, we produced a live CHIKV vaccine strain that combines the proven advantages of live-attenuated vaccines, yet which should be more stably attenuated than traditional approaches. This CHIKV vaccine is highly attenuated yet immunogenic in mouse models, and is incapable of replicating in mosquito cells. In this project, we will further develop this CHIK vaccine candidate in preparation for an investigational new drug application and Phase 1 human studies, using the following specific aims: 1. Determine the mechanism of vaccine attenuation by analyzing levels of RNA replication, protein expression and translational efficiency in vitro and patterns of replication and spread in vivo. 2. Define correlates of protective immunity and determine components of the innate and adaptive immune response required to control vaccine replication. 3. Optimize the vaccine candidate for production in Vero cells. 4. Develop and characterize GMP master virus seed and working virus seed stocks. 5. Develop quality control and release tests and manufacture a preclinical GMP lot of the vaccine. 6. Test the vaccine in nonclinical GLP studies for safety. 7. IND submission and manufacture of vaccine lots for Phase 1 clinical testing. The innovative product of this collaboration between academic and industrial partners will have dramatic impacts in Asia and Africa where CHIK causes both severe health effects and economic hardship, and will greatly reduce the risk of CHIKV importation and establishment in the Western Hemisphere. In addition, the improved mechanistic understanding of its attenuation and further development of our IRES-based vaccine platform technology will allow us to rapidly generate predictably safe and effective vaccines against other alphaviruses that represent biodefense threats and/or that have the potential that emerge in the future.

Public Health Relevance

In support of the mission of the NIH to improve health, we will develop a safe and effective vaccine to prevent chikungunya fever, a mosquito-borne viral disease that recently re-emerged to cause millions of cases of severe and often chronic arthralgia in Africa and Asia. This vaccine will not only prevent disease in endemic parts of the world, but will reduce the risk of importation into the U.S. and other parts of the Americas.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Repik, Patricia M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Medical Br Galveston
Schools of Medicine
United States
Zip Code
Langsjoen, Rose M; Haller, Sherry L; Roy, Chad J et al. (2018) Chikungunya Virus Strains Show Lineage-Specific Variations in Virulence and Cross-Protective Ability in Murine and Nonhuman Primate Models. MBio 9:
Weger-Lucarelli, James; Aliota, Matthew T; Wlodarchak, Nathan et al. (2016) Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity. J Virol 90:2418-33
Erasmus, Jesse H; Rossi, Shannan L; Weaver, Scott C (2016) Development of Vaccines for Chikungunya Fever. J Infect Dis 214:S488-S496
Weaver, Scott C; Costa, Federico; Garcia-Blanco, Mariano A et al. (2016) Zika virus: History, emergence, biology, and prospects for control. Antiviral Res 130:69-80
Weger-Lucarelli, James; Aliota, Matthew T; Kamlangdee, Attapon et al. (2015) Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses. PLoS Negl Trop Dis 9:e0004163
Seymour, Robert L; Adams, A Paige; Leal, Grace et al. (2015) A Rodent Model of Chikungunya Virus Infection in RAG1 -/- Mice, with Features of Persistence, for Vaccine Safety Evaluation. PLoS Negl Trop Dis 9:e0003800
Plante, Kenneth S; Rossi, Shannan L; Bergren, Nicholas A et al. (2015) Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate. PLoS Negl Trop Dis 9:e0004007
Sahadeo, Nikita; Mohammed, Hamish; Allicock, Orchid M et al. (2015) Molecular Characterisation of Chikungunya Virus Infections in Trinidad and Comparison of Clinical and Laboratory Features with Dengue and Other Acute Febrile Cases. PLoS Negl Trop Dis 9:e0004199
Weaver, Scott C (2014) Arrival of chikungunya virus in the new world: prospects for spread and impact on public health. PLoS Negl Trop Dis 8:e2921
Tretyakova, Irina; Hearn, Jason; Wang, Eryu et al. (2014) DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis 209:1882-90

Showing the most recent 10 out of 21 publications